Use of an ultra short-acting beta-blocker in patients with acute myocardial ischemia.
- 1 October 1985
- journal article
- abstracts
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 72 (4), 873-880
- https://doi.org/10.1161/01.cir.72.4.873
Abstract
Esmolol is a new ultra short-acting (half-life [t1/2] beta 9 min) beta 1-adrenergic-receptor antagonist reported to have no intrinsic sympathomimetic activity. The safety and efficacy of esmolol in lowering the ventricular rate and rate-pressure product in patients with acute myocardial infarction (n = 5), postmyocardial infarction angina (n = 10), or acute unstable angina (n = 4), and without cardiogenic shock were studied. After a 30 min observation period, esmolol was titrated to a maximum dose of 300 micrograms/kg/min and infused for up to 420 min. The ventricular rate fell from 92 +/- 11 (mean +/- SD) to 77 +/- 13 beats/min (p less than .01) and the systolic arterial pressure decreased from 120 +/- 13 to 97 +/- 11 mm Hg (p less than .01) during the initial 30 min titration period. There was no significant change during the maintenance phase, and both the ventricular rate and arterial pressure returned rapidly toward baseline values within 30 min of termination of the infusion. The cardiac index fell from 2.8 +/- 0.6 to 2.2 +/- 0.6 liters/min/m2 (p less than .01) during the same period, and also returned to the baseline level 30 min after termination of the infusion. There was no significant change in the pulmonary capillary wedge pressure, respiratory rate, or PR interval. Five patients required termination of infusion because of hypotension and all recovered uneventfully within 30 min of stopping the esmolol. One patient required a brief infusion of dopamine to restore hemodynamic stability.(ABSTRACT TRUNCATED AT 250 WORDS)Keywords
This publication has 31 references indexed in Scilit:
- Thrombolytic TherapyNew England Journal of Medicine, 1984
- Reduction of Infarct Size with the Early Use of Timolol in Acute Myocardial InfarctionNew England Journal of Medicine, 1984
- Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial InfarctionNew England Journal of Medicine, 1983
- Ultra-short acting beta-blockers: A proposal for the treatment of the critically ill patientLife Sciences, 1982
- Intravenous Beta-Blockade in Coronary Heart DiseaseNew England Journal of Medicine, 1982
- β-Adrenoceptor Antagonists: New Drugs and New IndicationsNew England Journal of Medicine, 1981
- Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial InfarctionNew England Journal of Medicine, 1981
- Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 4. Adverse effects. Choosing a β-adrenoreceptor blockerAmerican Heart Journal, 1979
- Adrenoceptor Blocking DrugsDrugs, 1979
- Adverse Reactions to ??-Adrenergic Receptor Blocking DrugsDrugs, 1974